论文部分内容阅读
目的探讨乳腺癌组织中膜-细胞骨架联接蛋白埃兹蛋白(ezrin)、肿瘤转移抑制因子(nm-23)和血管内皮生长因子(VEGF)等蛋白表达与乳腺癌临床因素及预后的关系。方法应用免疫组化S-P方法检测63例手术切除的乳腺癌组织标本中ezirn、nm-23、VEGF的表达,并与临床进行对比分析。结果ezirn、nm-23和VEGF阳性表达率分别为55.56%、52.38%和65.08%)。三项指标与淋巴结转移、临床分期及无病生存时间均密切相关(P<0.05),但与年龄、肿块大小及月经情况均无相关性。结论Ezirn、nm-23和VEGF在乳腺癌组织中表达较高,可能对其发展起促进作用,并可能作为评价预后的指标。
Objective To investigate the relationship between the expression of ezrin, nm-23 and vascular endothelial growth factor (VEGF) in breast cancer and the clinical factors and prognosis of breast cancer. Methods Immunohistochemical S-P method was used to detect the expression of ezirn, nm-23 and VEGF in 63 surgically resected breast cancer specimens and to compare with clinical data. Results The positive rates of ezirn, nm-23 and VEGF were 55.56%, 52.38% and 65.08%, respectively. The three indexes were closely related to lymph node metastasis, clinical stage and disease-free survival time (P <0.05), but no correlation with age, tumor size and menstrual status. Conclusion Ezirn, nm-23 and VEGF are highly expressed in breast cancer tissues, which may promote the development of Ezirn, nm-23 and VEGF, and may be used as an index to evaluate the prognosis.